10.5281/zenodo.3662379
https://zenodo.org/records/3662379
oai:zenodo.org:3662379
H. Sami , S. Barkiche , S. Elouarzazi , H. Eddaoualline , M. Darfaoui , I. Lalya , A. Elomrani and M. Khouchani
H. Sami , S. Barkiche , S. Elouarzazi , H. Eddaoualline , M. Darfaoui , I. Lalya , A. Elomrani and M. Khouchani
Radiation-Oncology Department, Mohammed VI University Hospital, Marrakech
HYPOFRACTIONATED RADIOTHERAPY IN BREAST CANCER: CAN IT BECOME A STANDARD
Zenodo
2020
Hypofractionated Radiotherapy Breast Cancer Survival
2020-01-20
10.5281/zenodo.3662378
Creative Commons Attribution 4.0 International
Radiation therapy has long demonstrated its benefit of local control in breast cancer, but also of recurrence and overall survival. However, this treatment is not stripped of constraints, essentially socio-economic: Few centers for a large number of patients, long duration of treatment occupying the majority of the activity of a radiotherapy service, high cost for patients living in remote regions. Which made think of more practical schemes in hypofractionation for a shorter duration of treatment. Indeed, hypofractionated radiotherapy is currently said to be equivalent to conventional irradiation in breast cancer in terms of local control for patients regardless of age or stage after conservative surgery, but not yet validated in the event of invasion lymph node or after mastectomy. Our study gathered 60 patients with breast cancer, at different stages, of which 75% had lymph node invasion and 72% operated by patey, with or without the presence of factors of poor prognosis (vascular embolism, SBR III, negative RH, Her2 positive), noting that only one patient had not received chemotherapy. The results in terms of overall survival and recurrence at 5 years after hypofractionated protocols have been very encouraging, which may suggest the adoption of these regimens more commonly.